Psoriatic Arthritis References

Last updated: 12 November 2024
Reviewed by
  1. Gossec L, Smolen JS, Gaujoux-Viala C, et al; European League Against Rheumatism. European League Against Rheumatism recommendations for the management of psoriatic arthritis with pharmacological therapies. Ann Rheum Dis. 2012 Jan;71(1):4-12. doi: 10.1136/annrheumdis-2011-200350. PMID: 21953336
  2. Gottlieb A, Korman NJ, Gordon KB, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. Section 2. Psoriatic arthritis: overview and guidelines of care for treatment with an emphasis on the biologics. J Am Acad Dermat. 2008 May;58(5):851-864. http://www.ncbi.nlm.nih.gov/pubmed/?term=Gottlieb+A%2C+Korman+NJ%2C+Gordon+KB%2C+et+al%09%22+Guidelines+of+care+for++the++management++of++psoriasis++and++psoriatic++arthritis.+Section+2.+Psoriatic+arthritis%3A+Overview+and+guidelines+of+care+for+treatment. PMID: 18423261
  3. Kyle S, Chandler D, Griffiths M, et al. Guideline for anti-TNF-alpha therapy in psoriatic arthritis. Rheumatology (Oxford). 2005 Mar;44(3):390-397. http://www.ncbi.nlm.nih.gov/pubmed/?term=Kyle+S%2C+Chandler+D%2C+Griffiths+M%2C+et+al%09%22+Guideline+for+anti-TNF-+alpha++therapy++in++psoriatic++arthritis%22. PMID: 15695305
  4. Ritchlin CT, Kavanaugh A, Gladman DD, et al. Treatment recommendations for psoriatic arthritis. Ann Rheum Dis. 2009 Sep;68(9):1387-1394. doi: 10.1136/ard.2008.094946. PMID: 18952643
  5. Moll JM, Wright V. Psoriatic arthritis. Semin Arthritis Rheum. 1973;3(1):55-78. http://www.ncbi.nlm.nih.gov/pubmed/4581554. PMID: 4581554
  6. Taylor W, Gladman D, Helliwell P, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006 Aug;54(8):2665-2673. http://www.ncbi.nlm.nih.gov/pubmed/?term=16871531. PMID: 16871531
  7. Van Voorhees A, Feldman SR, Koo JYM, et al. The psoriasis and psoriatic arthritis pocket guide: treatment algorithms and management options. The National Psoriasis Foundation; 2009.
  8. MedWormhttp://www.medworm.com/rss/index.php/Allergy-%26-Immunology/3/http://www.medworm.com/rss/medicalfeeds/specialities/Allergy-Immunology.xml
  9. MedWormhttp://www.medworm.com/rss/index.php/Pediatrics/33/http://www.medworm.com/rss/medicalfeeds/specialities/Pediatrics.xml
  10. Scottish Intercollegiate Guidelines Network (SIGN). Diagnosis and management of psoriasis and psoriatic arthritis in adults. SIGN. http://www.sign.ac.uk. 2010. Accessed 17 Jul 2011.
  11. National Institute for Health and Care Excellence (NICE). Golimumab for the treatment of psoriatic arthritis. NICE. http://www.nice.org.uk/. 2011.
  12. Coates L, Tillett W, Chandler P, et al. The 2012 British Society for Rheumatology guidelines for the treatment of psoriatic arthritis with biologicals. British Society for Rheumatology. http://www.rheumatology.org.uk/includes/documents/cm_docs/2012/b/bsr_guidelines_2012_treatment_of_psoriatic_arthritis_with_biologics.pdf. 2012. Accessed 24 Jul 2013.
  13. National Institute for Health and Care Excellence (NICE). Review of TA199; Etanercept, infliximab, and adalimumab for the treatment of psoriatic arthritis (includes a review of NICE technology appraisal guidance 104 and 125), and TA220; Golimumab for the treatment of psoriatic arthritis. NICE. http://www.nice.org.uk/. 2013.
  14. Coates LC, Kavanaugh A, Mease PJ, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 treatment recommendations for psoriatic arthritis. Arthritis Rheumatol. 2016 May;68(5):1060-1071. doi: 10.1002/art.39573. Accessed 09 Nov 2021. PMID: 26749174
  15. Gladman DD, Ritchlin C. Clinical manifestations and diagnosis of psoriatic arthritis. UpToDate. https://www.uptodate.com. 01 May 2020.
  16. Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020 Jun;79(6):700-712. doi: 10.1136/annrheumdis-2020-217159. PMID: 32434812
  17. Leung YY, Ogdie A, Orbai A, et al. Classification and outcome measures for psoriatic arthritis. Front Med (Lausanne). 2018;5:246. doi: 10.3389/fmed.2018.00246. PMID: 30238006
  18. National Institute for Health and Care Excellence (NICE). Psoriasis: assessment and management. NICE. https://www.nice.org.uk/. 01 Sep 2017.
  19. Noviani M, Feletar M, Nash P, et al. Choosing the right treatment for patients with psoriatic arthritis. Ther Adv Musculoskel Dis. 2020 Jan;12:1-7. doi: 10.1177/1759720X20962623. PMID: 33133245
  20. Ogdie A, Coates LC, Gladman DD. Treatment guidelines in psoriatic arthritis. Rheumatology (Oxford). 2020 Mar;59(Suppl 1):i37-i46. doi: 10.1093/rheumatology/kez383. PMID: 32159790
  21. Singh JA, Guyatt G, Ogdie A, et al. 2018 American College of Rheumatology/National Psoriasis Foundation guideline for the treatment of psoriatic arthritis. Arthritis Rheumatol. 2019 Jan;71(1):5-32. doi: 10.1002/art.40726. PMID: 30499246
  22. Smolen JS, Schöls M, Braun J, et al. Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. Ann Rheum Dis. 2018 Jan;77(1):3-17. doi: 10.1136/annrheumdis-2017-211734. PMID: 28684559
  23. Tillett W, Allen A, Tucker L, et al. Treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs: British Society for Rheumatology guideline scope. Rheumatology (Oxford). 2021 Apr;60(4):1588-1592. doi: 10.1093/rheumatology/keaa526. Accessed 08 Nov 2021. PMID: 33097948
  24. Tucker LJ, Coates LC, Helliwell PS. Assessing disease severity in psoriatic arthritis: a literature review. Rheumatol Ther. 2019 Mar;6(1):23-32. doi: 10.1007/s40744-018-0132-4. PMID: 30471015
  25. Carneiro S, Palominos PE, Anti SMA, et al. Brazilian Society of Rheumatology 2020 guidelines for psoriatic arthritis. Adv Rheumatol. 2021 Nov 24;61(1):69. doi: 10.1186/s42358-021-00219-y. PMID: 34819174
  26. Tsai TF, Hsieh TY, Chi CC, et al; Taiwan Rheumatology Association (TRA) and the Taiwanese Association for Psoriasis and Skin Immunology (TAPSI). Recommendations for psoriatic arthritis management: a joint position paper of the Taiwan Rheumatology Association and the Taiwanese Association for Psoriasis and Skin Immunology. J Formos Med Assoc. 2021 Mar;120(3):926-938. doi: 10.1016/j.jfma.2020.08.026. PMID: 33012636
  27. Brent LH. Psoriatic arthritis. StatPearls. https://www.ncbi.nlm.nih.gov. 11 Aug 2021.
  28. Thomas S. Management of psoriatic arthritis. J Skin Sex Transm Dis. 2019;1(1):13-18. doi: 10.25259/JSSTD_16_2019.
  29. Kavanaugh A, Mease PJ, Gomez-Reino JJ, et al. Treatment of psoriatic arthritis in a phase 3 randomised, placebo-controlled trial with apremilast, an oral phosphodiesterase 4 inhibitor. Ann Rheum Dis. 2014 Jun;73(6):1020-1026. doi: 10.1136/annrheumdis-2013-205056. PMID: 24595547
  30. Wofford J, Menter A. Ustekinumab for the treatment of psoriatic arthritis. Expert Rev Clin Immunol. 2014 Feb;10(2):189-202. doi: 10.1586/1744666X.2014.878649. PMID: 24410536
  31. Remillard MA, Durand C. New GRAPPA treatment recommendations for psoriatic arthritis. The Medical Xchange. https://themedicalxchange.com. 2021.
  32. Fitzgerald O. Psoriatic arthritis. In: Firestein GS, Budd RC, Gabriel SE, et al. Kelley’s Textbook of Rheumatology. 9th ed. Philadelphia, PA: Elsevier, Inc; 2013.
  33. U.S. Food & Drug Administration (US FDA). BLA 125261 Stelara (ustekinumab). Risk evaluation and mitigation strategy (REMS). US FDA. http://www.fda.gov/. Sep 2013.
  34. U.S. Food & Drug Administration (US FDA). FDA news release: FDA approves Otelza to treat psoriatic arthritis. US FDA. http://www.fda.gov/. Mar 2014.
  35. U.S. Food & Drug Administration (US FDA). Abrilada highlights of prescribing information. US FDA. https://www.fda.gov/. Nov 2019. Accessed 18 Aug 2022.
  36. Azuaga AB, Ramírez J, Cañete JD. Psoriatic arthritis: pathogenesis and targeted therapies. Int J Mol Sci. 2023 Mar;24(5):4901. doi: 10.3390/ijms24054901. PMID: 36902329
  37. Coates LC, Soriano ER, Corp N, et al. Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA): updated treatment recommendations for psoriatic arthritis 2021. Nat Rev Rheumatol. 2022 Aug;18(8):465-479. doi: 10.1038/s41584-022-00798-0. PMID: 35761070
  38. Gladman DD, Ritchlin C. Pathogenesis of psoriatic arthritis. UpToDate. https://www.uptodate.com. 01 Feb 2022.
  39. Gladman DD, Ritchlin C. Treatment of psoriatic arthritis. UpToDate. https://www.uptodate.com. 06 Mar 2023.
  40. Tucker L, Allen A, Chandler D, et al. The 2022 British Society for Rheumatology guideline for the treatment of psoriatic arthritis with biologic and targeted synthetic DMARDs. Rheumatology (Oxford). 2022 Aug;61(9):e255-e266. doi: 10.1093/rheumatology/keac295. PMID: 35640657
  41. Gossec L, Kerschbaumer A, Ferreira RJO, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2023 update. Ann Rheum Dis. 2024 Mar 18:ard-2024-225531. doi: 10.1136/ard-2024-225531. PMID: 38499325
  42. Lloyd P, Ryan C, Menter A, et al. Psoriatic arthritis: an update. Arthritis. 2012:176298. doi: 10.1155/2012/176298. PMID: 23209897